ProCE Banner Activity

BTK Inhibitors in CLL/SLL and MCL: The Latest Guidance and Evidence for the Clinic

Clinical Thought

My take on the latest guidance, key evidence, and important safety considerations for the expert management of CLL/SLL and MCL using BTK inhibitors.

Released: December 14, 2023

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, FAPO: consultant/advisor/speaker: GlaxoSmithKline, Janssen, Sanofi.